• 諮詢熱線+852 3480 8393

Logo
  • 首頁
  • 公司介紹
    • 背景
    • 免疫治療日本
    • 免疫治療香港
    • 腫瘤科醫生
  • 免疫細胞治療
    • 免疫細胞治療/自體免疫療法
    • 樹突狀細胞/DC疫苗療法
    • 自然殺傷細胞/NK細胞療法
    • 淋巴因子活化殺傷細胞(殺手T細胞)療法
    • 免疫治療成功率
    • 免疫治療副作用
    • 免疫治療費用
  • 醫生介紹
    • 日本
    • 香港
  • 癌症預防/防復發
    • 癌症復發率
    • 癌症預防
  • 新聞及臨床報告
    • 新聞
    • 臨床醫學報告
  • 聯絡我們

新聞及臨床報告

  • 首頁
  • 新聞及臨床報告
  • 臨床醫學報告
首頁 > 新聞及臨床報告 > 臨床醫學報告 > Dendritic Cell–Based Immunotherapy: State of the Art and Beyond

Dendritic Cell–Based Immunotherapy: State of the Art and Beyond

  • Clinical Cancer Research
  • 2022-06-17
  • 0 次瀏覽

https://aacrjournals.org/clincancerres/article/22/8/1897/265865/Dendritic-Cell-Based-Immunotherapy-State-of-the


Abstract

Dendritic cell (DC) vaccination in cancer patients aims to induce or augment an effective antitumor immune response against tumor antigens and was first explored in a clinical trial in the 1990s. More than two decades later, numerous clinical trials have been performed or are ongoing with a wide variety of DC subsets, culture protocols, and treatment regimens. The safety of DC vaccination and its ability to induce antitumor responses have clearly been established; however, although scattered patients with long-term benefit were reported, DC vaccines have not yet fulfilled their promise, perhaps mainly due to the lack of large-scale well-conducted phase II/III trials. To allow meaningful multicenter phase III trials, the production of DC vaccines should be standardized between centers which is now becoming feasible. To improve the efficacy of DC-based immunotherapy, it could be combined with other treatments. Clin Cancer Res; 22(8); 1897–906. ©2016 AACR.


Source: Kalijn F. Bol; Gerty Schreibelt; Winald R. Gerritsen; I. Jolanda M. de Vries; Carl G. Figdor. Dendritic Cell–Based Immunotherapy: State of the Art and Beyond

上一篇:Review of Dendritic Cells, Their Role in Clinical Immunology, and Distribution in Various Animal Species 下一篇:Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses

欄目分類

  • 新聞 11
  • 臨床醫學報告 13

熱門文章

  • Targeting dendritic cells in pancreatic ductal adenocarcinoma
    2022-06-17
  • Modified Immunotherapy Approach Shows Promise for Leukemia Subscribe
    2022-06-17
  • Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma
    2022-06-17
  • Dendritic Cell–Based Immunotherapy: State of the Art and Beyond
    2022-06-17
  • WT1 (Wilms' Tumor Gene 1): Biology and Cancer Immunotherapy
    2022-06-17
  • Targeted Cancer Therapy by Dendritic Cell Vaccine
    2022-06-17
  • Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment
    2022-06-17
  • NK cell-based cancer immunotherapy: from basic biology to clinical development
    2022-06-17
  • Cancer immunotherapy via dendritic cells
    2022-05-05
Logo
  • 郵箱:info@asiaimmune.com
  • 電話:+852 3480 8393
  • 微信:aicl_hk

免疫細胞治療

  • 免疫細胞治療/自體免疫療法
  • 樹突狀細胞/DC疫苗療法
  • 自然殺傷細胞/NK細胞療法
  • 淋巴因子活化殺傷細胞(殺手T細胞)療法
  • 免疫治療成功率
  • 免疫治療副作用
  • 免疫治療費用

合作機構

  • 日本新橫濱加藤醫院

公司地址

  • 九龍尖沙咀漢口道28號亞太中心8樓812室
  • +852 3480 8393

Copyright © 2022. Designed by Asia Immunotherapy Company Limited.